Loading live market data…

BioHarvest Sciences Inc. Common Stock

NASDAQ:BHST

$2.79 USD

$0.02 (0.72%)

Volume
31.84K
Average Volume
29.77K
Market Capitalization
$48.34M
P/E Ratio
-4.50
Dividend Yield
0.00%
Price Target
$10.00
Year High
$12.80
Year Low
$2.70
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$2.96
Source Headline
BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026. Presentation Details: Date/Time: Wednesday, July 22, 2026 at 10:00 a.m.

newsfilecorp.com - 2026-07-13 08:00:00

BioHarvest Sciences to Present at the 2026 BIO International Convention

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details: Session: Company Presentation Date/Time: Wednesday, June 24, 11:45 AM Location: Theater 3 BioHarvest Sciences' presentation will showcase its proprietary Botanical Synthesis™ platform, which enables the production of plant-derived compounds with pharmaceutical-grade precision, consistency, and commercial scalability, opening new possibilities in drug discovery, active pharmaceutical ingredients, and next-generation therapeutics.

newsfilecorp.com - 2026-06-18 07:30:00

BioHarvest Sciences and Tate & Lyle expand sweetener development program

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration with Tate & Lyle PLC (LSE:TATE) to broaden the scope of their joint sweetener development program to include multiple plant-based sweetener molecules. The expanded partnership builds on an agreement signed in 2024 and follows what the companies described as strong technical progress in developing sweetening solutions for food and beverage manufacturers.

proactiveinvestors.com - 2026-05-19 08:41:38

Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories. Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their joint sweetener development program to include multiple plant-based sweetener molecules.

newsfilecorp.com - 2026-05-18 07:00:00

BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript

BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-14 13:50:47

BioHarvest Sciences Q1 Earnings Call Highlights

BioHarvest Sciences NASDAQ: BHST reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, platform.

marketbeat.com - 2026-05-14 10:09:45

BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the company advanced several contract development and manufacturing organization (CDMO) projects and expanded its direct-to-consumer wellness business. The company posted first quarter revenue of $8.5 million, up from $7.9 million a year earlier, while maintaining its full-year revenue guidance range of $42 million to $48 million.

proactiveinvestors.com - 2026-05-14 08:53:27

BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.

zacks.com - 2026-05-14 08:11:06

BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of April Two-lens framework enacted in Q1 to optimize performance across CDMO and D2C businesses Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 14, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced its first quarter 2026 financial results. The Company will hold a conference call this morning at 8:00 am Eastern Daylight Time (EDT) to discuss the results and provide an update on business operations.

newsfilecorp.com - 2026-05-14 07:00:00

BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division

Business development appointment is aligned with securing long-term customers for development and manufacturing partnerships Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceutical, nutrition, and cosmetic areas for BioHarvest's contract development and manufacturing organization (CDMO) business.

newsfilecorp.com - 2026-05-13 17:32:00

BioHarvest Sciences advances synthetic saffron program with SaffronTech partnership

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said that it has completed the first stage of a multi-stage development agreement with SaffronTech, establishing a stable saffron cell bank that the company says could one day offer a sustainable alternative to one of the world's most expensive agricultural commodities. The Nasdaq-listed biotech said completion of Stage 1 has triggered the start of Stage 2 under the ongoing agreement, which will focus on using its patented Botanical Synthesis platform to generate enough biomass to support pre-commercial testing and product development for nutraceutical and culinary applications.

proactiveinvestors.com - 2026-05-13 09:50:24

BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications

- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals - In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Columbia and Rehovot, Israel---(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has completed Stage 1 under a multi-stage development agreement, successfully establishing a stable saffron cell bank for potential nutraceutical and culinary applications. The development partner is SaffronTech, a company pioneering advanced cultivation methods for saffron, one of the world's most valuable and health-promoting botanicals.

newsfilecorp.com - 2026-05-13 08:00:00

Alibaba shares jump as AI cloud surge offsets mixed quarterly results

Alibaba Group (NYSE:BABA) shares climbed nearly 7% in early Wednesday trading after the Chinese e-commerce and technology giant reported fourth-quarter...

proactiveinvestors.com - 2026-05-13 06:57:00

BioHarvest Sciences wins $1.2M fragrance contract

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has secured a $1.2 million Stage 2 contract to develop a rare scent-producing plant compound for the global fragrance industry, marking a key step in the firm's push into a market the company values at $23 billion. The contract, awarded by a United Arab Emirates-based investment group, is part of a multi-stage development program for a fragrance raw material described as among the most valuable in the world, with premium grades fetching tens of thousands of dollars per kilogram.

proactiveinvestors.com - 2026-05-12 09:12:35

Plug Power reports first quarter earnings beat on narrower losses, margins progress

Plug Power (NASDAQ:PLUG) reported first quarter 2026 results that exceeded revenue expectations and showed continued improvement in profitability metrics,...

proactiveinvestors.com - 2026-05-12 08:57:00

BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform

Source plant is widely regarded as one of the most valuable fragrance raw materials in the world Stage 2 contract follows successful Stage 1 completion in March 2026 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 12, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has signed a $1.2 million-dollar Stage 2 contract as part of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. This scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand growing across the Middle East, Asia, and luxury Western perfume markets.

newsfilecorp.com - 2026-05-12 07:30:00

Will BioHarvest Sciences Inc. (BHST) Report Negative Earnings Next Week? What You Should Know

BioHarvest Sciences Inc. (BHST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-05-07 11:00:48

BioHarvest Sciences to Report First Quarter 2026 Financial Results on May 14, 2026

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - April 30, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its first quarter 2026 financial results before the market opening on Thursday, May 14, 2026. The Company will also host a conference call and webcast at 8:00 a.m.

newsfilecorp.com - 2026-04-30 16:05:00

Alphabet tops quarterly revenue and profit estimates on Google Cloud surge

Alphabet Inc (NASDAQ:GOOG) reported first quarter results that beat Wall Street expectations, sending its shares almost 4% higher after Wednesday’s closing...

proactiveinvestors.com - 2026-04-29 12:44:00

BioHarvest Sciences names co-founder Rakib as CEO in leadership transition

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has appointed co-founder Dr Zaki Rakib as CEO, consolidating leadership of its research, manufacturing, and operations under a unified structure as the botanical technology company sharpens its growth strategy. Rakib, who previously served as executive chairman, will take charge of the company's contract development and manufacturing organization (CDMO) division.

proactiveinvestors.com - 2026-04-29 09:10:32

BioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate "Two-Lens" Growth Strategy

Ilan Sobel joins Board of Directors with focused mandate on D2C growth. Dr. Zaki Rakib, Co-Founder and Executive Chairman, assumes role of Chief Executive Officer, Integrating R&D, Manufacturing, and Operations under the CDMO.

newsfilecorp.com - 2026-04-29 08:30:00

GE HealthCare shares tumble after profit miss and guidance cut

GE Healthcare Technologies Inc (NASDAQ:GEHC) shares fell sharply on Wednesday after the medical imaging company reported first-quarter earnings that missed...

proactiveinvestors.com - 2026-04-29 06:55:00

Robinhood misses Q1 revenue estimates as crypto trading slumps

Robinhood Markets Inc (NASDAQ:HOOD) fell short of first-quarter revenue expectations as a sharp decline in cryptocurrency trading revenue weighed on...

proactiveinvestors.com - 2026-04-29 05:53:00

Get BHST Insider Trade Alerts

BHST Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$0.00

0 analysts

Last Year

$10.00

1 analysts

All Time

$12.33

3 analysts

BHST Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2025-04-08 HC Wainwright & Co. Maintain Buy Buy
2024-12-11 HC Wainwright & Co. Maintain Buy Buy